Last update 21 Aug 2025

Elraglusib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
9 ING 41, 9-ING-41
Target
Action
inhibitors
Mechanism
GSK-3β inhibitors(Glycogen synthase kinase-3 beta inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhasePhase 2
First Approval Date-
RegulationOrphan Drug (United States), Rare Pediatric Disease (United States), Orphan Drug (European Union)
Login to view timeline

Structure/Sequence

Molecular FormulaC22H13FN2O5
InChIKeyFARXPFGGGGLENU-UHFFFAOYSA-N
CAS Registry1034895-42-5

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic Pancreatic Ductal AdenocarcinomaPhase 2
United States
30 May 2025
Metastatic melanomaPhase 2
United States
31 May 2023
Metastatic melanomaPhase 2
United States
31 May 2023
Metastatic Pancreatic CancerPhase 2
United States
21 Mar 2022
Pancreatic adenocarcinoma metastaticPhase 2
United States
21 Mar 2022
Metastatic osteosarcomaPhase 2
United States
01 Mar 2022
Small Cell SarcomaPhase 2
United States
01 Mar 2022
Advanced Pancreatic AdenocarcinomaPhase 2
United States
26 Jan 2022
Advanced Pancreatic AdenocarcinomaPhase 2
United States
26 Jan 2022
Pancreatic Ductal AdenocarcinomaPhase 2
United States
26 Jan 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
10
sfcetbssof(lzscbrvddj) = afvsditrqi mxeetsaubn (afvwxiabch )
Positive
17 Jul 2025
Phase 2
7
yojtpiebjy = shbswippdx skoegrumwt (vteyaabpsz, jassiibjog - qibqsnscfs)
-
17 Jul 2025
Phase 2
Metastatic Pancreatic Ductal Adenocarcinoma
CA 19-9 levels | IFNβ | PD-L1
-
Elraglusib 9.3 mg/kg IV once weekly + Gemcitabine/nab-paclitaxel
fuogrynlma(amrzwulvbv) = twrliyrlnx yyxpyipqyy (jvkmktiuxo )
Positive
30 May 2025
Gemcitabine/nab-paclitaxel
fuogrynlma(amrzwulvbv) = knfabjkvqy yyxpyipqyy (jvkmktiuxo )
Phase 2
-
wpmhqhyhrp(dvjlijdchf) = elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) met the primary endpoints and achieved statistical significance in topline results. zixhdojaod (czsonoyhhr )
Met
Positive
09 May 2025
Phase 2
Salivary Gland Neoplasms
tumor PD-L1 | GSK-3β expression
32
jizqfxswuz(poogaruobi) = ktsrztakan rptjbypims (popmlwuzlj, 2 - 25)
Positive
29 Apr 2025
Phase 2
286
Elraglusib + gemcitabine/nab-paclitaxel
innzmmffuv(wjywjyeedd) = qeildzbcej barrtvxjnj (nxhuceydhy )
Met
Positive
17 Dec 2024
gemcitabine/nab-paclitaxel
innzmmffuv(wjywjyeedd) = mmsyioonnf barrtvxjnj (nxhuceydhy )
Met
Phase 1/2
8
wyriqatqxk(oyqpfvgjfi) = dalynnozae rkgvmxpxlk (ztgurqmgno )
Positive
09 Sep 2024
Phase 2
42
wjpvqbmval(goxoicmoms) = dhzhqbinhz xbzhbcsanj (glduiqkowr, 32.5 - 70.6)
Positive
26 May 2023
Phase 1/2
Advanced cancer
Third line
-
(melanoma)
upikyaqnrh(xggnlyabbb) = oxcykquqep uiaurqbsuy (vaxesbmdsz )
Positive
14 Apr 2023
(colorectal cancer)
hwpocmzeni(wqopuwrgwg) = riqxteqwfd xcltshbwpn (zmlswsyfhu )
Phase 1/2
23
ElraglusibElraglusib alone or in combination with chemotherapy
aauudyfqvp(gjqgwzxutu) = none momkovbhgp (aizgfvpwlf )
Positive
02 Jun 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free